Clinical and Biochemical Features for the Identification of Dominant Calpainopathies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-09-01

Study Completion Date

2025-06-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Mutations in the CAPN3 gene cause muscular dystrophies with dysfunction in calpain-3. Calpainopathies are usually inherited in an autosomal recessive manner but in some families they can occur in a dominant inheritance. The significance of heterozygous variants is difficult to interpret in the absence of family history. In this study, the investigators will review the clinical and laboratory information in a cohort of patients identified in the participating centers, with the aim of improving the diagnostic strategy of dominant calpainopathies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Importance of Carrier Status of Recessive Gene Mutations in Myopathy (CICS)

NCT02897921

Recessive Gene Myopathies

UNKNOWN

Genetic and Physical Study of Childhood Nerve and Muscle Disorders

NCT01568658

Muscular Dystrophies Muscle Myopathies Hereditary Spastic Paraplegias +2 more

RECRUITING

Genetic Polymorphisms Associated With Vertebral Osteochondrosis

NCT04195529

Spinal Osteochondrosis

UNKNOWN

Phenotype/Genotype Correlations in Neuromuscular Disorders

NCT00017745

Neuromuscular Disease

COMPLETED

Genetic and Family Studies of Inherited Muscle Diseases

NCT00001331

Dermatomyositis Glycogen Storage Disease Type II Glycogen Storage Disease Type VII +2 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators will review clinical and biomarker information in a cohort of 50 patients with heterozygous variants in the CAPN3 gene. Patients are referred by participating centers who will provide anonymised information on the clinical phenotype and laboratory test results. Suitable subjects will be contacted to obtain informed consent. Pseudonymised anamnestic data will be collected from the patient's clinical history and medical records.The aim is to identify a set of multidisciplinary data sufficient to define a diagnostic algorithm for the dominant calpainopathies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Calpain-3 Deficiency Limb Girdle Muscular Dystrophy Type 2A

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

retrospective study

data collection from clinical history and medical records

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical LGMD phenotype, family history with dominant inheritance or sporadic cases, single variant in CAPN3, second variant excluded by MLPA (Multiplex Ligation Probe Amplification) or by analysis of mRNA extracted from muscle.